Jubilant-Endo meet early stage milestone in oncology deal
This article was originally published in Scrip
Jubilant Biosys, a subsidiary of India's Jubilant Organosys, and Endo Pharmaceuticals of the US have met an early stage milestone in one of the collaborative programmes.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.